drugset / Trial / NCT04485039
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
Phase 4
Completed
44 enrolled
SIGA Technologies
Biomedical Advanced Research and Development Authority · collabPPD Development, LP · collab
RandomizedCrossoverOpen-labelOther
Summary
An open-label, drug-drug interaction study with TPOXX and phosphate binders.
Timeline
- Start
- 2022-06-08
- Primary completion
- 2022-12-15
- Completion
- 2023-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcium carbonate | Other / unclassified | 1334 mg | Oral |
| Subject | Lanthanum Carbonate | Other / unclassified | 500 mg | Oral |
| Subject | PA21 | Unknown | 500 mg | Oral |
| Subject | Tecovirimat | Small molecule | 600 mg | Oral |
| Subject | sevelamer | Other / unclassified | 1600 mg | Oral |